South Korea fines JPMorgan, Morgan Stanley, Nomura and UBS for short selling breaches
South Korea's market watchdog has decided to impose fines on JPMorgan, Morgan Stanley, Nomura and UBS for violating ...
UBS has preference for high-quality dividend stocks in Switzerland
Despite ongoing political uncertainty and trade disputes, UBS maintains a positive outlook on the fundamental economic environment. This optimism is underpinned by robust economic growth in the United ...
UBS Wealth Calls Out Payment Triggers for Catastrophe Bonds
The models that determine when catastrophe bonds pay out are falling short, as the financial compensation triggered by ...
UBS whistleblower verdict thrown out despite US Supreme Court win
A former UBS bond strategist who persuaded the U.S. Supreme Court to make it easier for corporate whistleblowers to win ...
UBS Group Cuts CVS Health (NYSE:CVS) Price Target to $59.00
CVS Health (NYSE:CVS – Free Report) had its price objective decreased by UBS Group from $62.00 to $59.00 in a research note ...
UBS Reaffirms Their Hold Rating on GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh (GQG)
In a report released today, Shreyas Patel CFA from UBS maintained a Hold rating on GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh ...
UBS CEO expects more clarity on capital rules in May
UBS should have more clarity on the amount of capital it will need to hold under new Swiss banking regulations currently ...
Compass upgraded to Buy at UBS on acquisition benefits, expected market share gains
UBS upgraded Compass (COMP) to Buy on the premise that the real estate brokerage stock isn't reflecting the company's recent ...
UBS upgrades Interpublic Group to Neutral on high odds of Omnicom deal closing
As previously reported, UBS upgraded Interpublic Group (IPG) to Neutral from Sell with a price target of $27, down from $29, citing the firm’s ...
UBS notes European gas storage below average, US stocks see larger draw
UBS released data indicating that European gas storage levels are below the five-year average, with storage facilities ...
Roche upgraded by UBS to buy on growth outlook
UBS has upgraded Roche (OTCQX:RHHBY) to buy from neutral, citing the company's growth outlook. "We see sustained outperformance of Vabysmo and Ocrevus as key drivers of near-term growth, with ...